Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 33

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

439

HTML

3112

Figures (1-7)

234

Sum=3785

Sep 7, 2007 (publication date) through Nov 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Sep 7, 2007; 13(33): 4458-4466
Published online Sep 7, 2007. doi: 10.3748/wjg.v13.i33.4458

Full Size Figure Download Figure

Figure 7 Anti-proliferative effects of MS-275 plus sorafenib or bortezomib on EGI-1 and TFK-1. mean ± SEM, n = 3-4 independent experiments.

Citation: Baradari V, Höpfner M, Huether A, Schuppan D, Scherübl H. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007; 13(33): 4458-4466
URL: https://www.wjgnet.com/1007-9327/full/v13/i33/4458.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i33.4458